Eli Lilly announced on Wednesday that it has initiated six lawsuits against wellness vendors. These vendors are allegedly selling unauthorized versions of its experimental weight-loss drug, retatrutide. The company aims to curb the rising tide of illegal online sales of this potent drug.
A vial of Retatrutide photographed in Brooklyn, New York, highlights the ongoing issue. According to Eli Lilly, the unauthorized distribution of retatrutide by these vendors constitutes a significant problem, prompting the legal action.

The Future of MAHA in American Health Politics
Insulin Cost Caps Gaining Support Amid Rising Prices
A Personal Journey Through Encephalitis
Low-Cost Medication May Benefit Stroke Survivors
The Complex Debate Over Kratom Use in the U.S.
Florida’s Struggle with Dengue Fever and AI Solutions